{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:40:02Z","timestamp":1786650002968,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"abstract":"\n Objectives:<\/jats:title>\n Acute lymphoblasstic leukemia (ALL) is the most common childhood malignancy. Prominin-1 is a cell-surface trans-membrane glycoprotein expressed on the stem cell surface and has potential role in diagnostic and prognostic work-up of several stem cell cancers.<\/jats:p>\n <\/jats:sec>\n \n Aim of this Work:<\/jats:title>\n To assess the prognostic value of Prominin-1 expression in Egyptian children with ALL.<\/jats:p>\n <\/jats:sec>\n \n Subjects and Methods:<\/jats:title>\n This study was conducted on 80 Egyptian children with newly diagnosed ALL and 30 healthy children of matched age and sex as a control group. Patient history, and clinical and laboratory examination results were taken, including complete blood count, serum LDH, bone marrow aspiration with cytochemistry, immunophenotyping, Fluorescent In Situ Hybridization technique for detection of t(9;22) and Flow cytometery for estimation of Prominin-1 expression on blast cells.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n No statistically significant differences were observed between Prominin-1 positive and negative patients regarding age, sex and clinical presentation at diagnosis. No statistically significant differences between Prominin-1 positive and negative patients were observed regarding white blood cells and platelet counts, peripheral blood and bone marrow blast cells percentage while there were significantly higher hemoglobin and LDH levels in Prominin-1 positive patients. There were no significant differences between Prominin-1 positive and negative patients regarding immunophenotyping and t(9;22). There were statistically significant differences in disease outcome between Prominin-1 positive and negative expression with higher rate of relapse and death and lower rate of complete remission in patients with Prominin-1 positive expression (14 cases with Prominin-1 positive relapsed versus 2 cases with Prominin-1 negative, 12 cases with Prominin-1 positive died versus 2 cases with Prominin-1 negative and complete remission occurred in 20 cases with Prominin-1 positive versus 30 cases with Prominin-1 negative) (\n P<\/jats:italic>\n =0.017). There was statistically significant difference in disease-free survival (\n P<\/jats:italic>\n = 0.0072) and overall survival (\n P<\/jats:italic>\n = 0.0424) between ALL patients with Prominin-1 positive and Prominin--1 negative expression.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Prominin-1 is a helpful prognostic marker in patients with ALL; therefore, it should be routinely assessed at diagnosis in ALL patients for better prognostic assessment and should be taken in consideration in designing future therapeutic strategies based on patient-specific risk factors.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/0973-1482.148717","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T05:33:49Z","timestamp":1469511229000},"page":"627-633","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of Prominin-1 Expression in Egyptian children with Acute Lymphoblastic Leukemia: Two centers Egyptian study"],"prefix":"10.4103","volume":"12","author":[{"given":"Adel A.","family":"Hagag","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada M.","family":"Elmashad","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Faculty of Medicine, Elmenofia University, Elsadat, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enaam S.","family":"Abd El-Bar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/1078155213508439","article-title":"Prognostic value of plasma levels of thrombomodulin and von Willebrand factor in Egyptian children with acute lymphoblastic leukemia","volume":"20","author":"Hagag","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"R2-20260109","first-page":"896","article-title":"Applying the principles of stem cell biology to cancer","volume":"3","author":"Paradal","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.2283","article-title":"CD133 molecule of the moment","volume":"214","author":"Mizrak","year":"2008","journal-title":"J Pathol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1021\/bi900159d","article-title":"The Stem cell marker CD133 (Prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases","volume":"48","author":"Boivin","year":"2009","journal-title":"Biochemistry"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1634\/stemcells.2004-0317","article-title":"CD133 positive hematopoietic stem cell \u201cstemness\u201d genes contain many genes mutated or abnormally expressed in leukemia","volume":"23","author":"Toren","year":"2005","journal-title":"Stem Cells"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1472-6793-8-13","article-title":"Extended flow cytometry characterization of normal bone marrow progenitor cells by simultaneous detection of aldehyde dehydrogenase and early hematopoietic antigens: Implication for erythroid differentiation studies","volume":"8","author":"Mirabelli","year":"2008","journal-title":"BMC Physiol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2184.2006.00386.x","article-title":"Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+and CD133+blood stem cells derived from a single donor","volume":"39","author":"Freund","year":"2006","journal-title":"Cell Prolif"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/146532401317248054","article-title":"CD133 (AC133) expression on AML cells and progenitors","volume":"3","author":"Vercauteren","year":"2001","journal-title":"Cytotherapy"},{"key":"R9-20260109","first-page":"470","article-title":"Expression of CD133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome","volume":"15","author":"Wang","year":"2007","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"R10-20260109","first-page":"46","article-title":"The expression and clinical significance of early differentiation antigens in acute leukemia","volume":"44","author":"Zhou","year":"2005","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood-2006-12-061689","article-title":"Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: A report from the Children's Oncology Group P9201","volume":"110","author":"Chauvenet","year":"2007","journal-title":"Blood"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early post induction intensification therapy improves survival for children and adolescents with high risk acute lymphoblastic leukemia: A report from the Children's Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","article-title":"Childhood T cell acute lymphoblastic leukemia. The Dana-Farber Cancer Institute. Acute lymphoblastic leukemia consortium experience","volume":"21","author":"Goldberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"819","DOI":"10.5604\/17322693.968778","article-title":"Tyrosine kinase inhibitors in hematological malignancies","volume":"65","author":"Kosior","year":"2011","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nri1416","article-title":"Seventeen-colour flow cytometry: Unravelling the immune system","volume":"4","author":"Perfetto","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"R22-20260109","first-page":"171","article-title":"Fluorescence in situ hybridization (FISH)","volume":"1","author":"O'Connor","year":"2008","journal-title":"Nat Educ"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1179\/102453308X316103","article-title":"CD133-2(AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein","volume":"13","author":"Guenova","year":"2008","journal-title":"Hematology"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MPH.0b013e3181c80c08","article-title":"AC133 expression in Egyptian children with acute leukemia: Impact on treatment response and disease outcome","volume":"32","author":"Elgendi","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R27-20260109","first-page":"401","article-title":"The expression of CD133 in acute leukemia and its clinical significance","volume":"25","author":"Zhou","year":"2004","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2008-04-154187","article-title":"Expression of CD133 on leukemia-initiating cells in childhood ALL","volume":"113","author":"Cox","year":"2009","journal-title":"Blood"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumor stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-11-3589","article-title":"The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription","volume":"72","author":"Mak","year":"2012","journal-title":"Cancer Res"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1476-4598-12-165","article-title":"In triple negative breast tumor cells, PLC-\u03b22 promotes the conversion of CD133 high to CD133 low phenotype and reduces the CD133-related invasiveness","volume":"12","author":"Brugnoli","year":"2013","journal-title":"Mol Cancer"},{"key":"R32-20260109","first-page":"2644","article-title":"Prognostic value of cancer stem cell CD133 expression in non-small cell lung cancer: A systemic review","volume":"6","author":"Qu","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4149\/neo_2014_021","article-title":"CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential","volume":"61","author":"Zhang","year":"2014","journal-title":"Neoplasma"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201612020-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:58Z","timestamp":1786647658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201612020-00033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.148717","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}